Economic incentives for HIV testing by adolescents in Zimbabwe: a randomised controlled trial.

Abstract:

BACKGROUND:HIV testing is the important entry point for HIV care and prevention service, but uptake of HIV testing and thus coverage of antiretroviral therapy are much lower in older children and adolescents than in adults. We investigated the effect of economic incentives provided to caregivers of children aged 8-17 years on uptake of HIV testing and counselling in Harare, Zimbabwe. METHODS:This randomised controlled trial was nested within a household HIV prevalence survey of children aged 8-17 years in Harare. Households with one or more survey participants whose HIV status was unknown were eligible to participate in the trial. Eligible households were randomly assigned (1:1:1) to either receive no incentive, receive a fixed US$2 incentive, or participate in a lottery for $5 or $10 if the participant presented for HIV testing and counselling at a local primary health-care centre. The survey fieldworkers who enrolled participants were not blinded to trial arm allocation, but the statistician was blinded for analysis of outcome. The primary outcome was the proportion of households in which at least one child had an HIV test within 4 weeks of enrolment. HIV test uptake in the incentivised groups was compared with uptake in the non-incentivised group using logistic regression, adjusting for community and number of children as fixed effects and research assistant as a random effect. All analyses were by intention to treat. The trial is registered with the Pan African Clinical Trials Registry, number PACTR201605001615280. FINDINGS:Between Aug 4, and Dec 18, 2015, 2050 eligible households were enrolled in the prevalence survey. 649 (32%) households were assigned no incentive, 740 (34%) households were assigned a $2 incentive, and 661 (32%) households were assigned to lottery participation. Children were unavailable in 148 households in the no-incentive group, 63 households in the $2 incentive group, and 81 households in the lottery group. 1688 households had at least one child with unknown HIV status and were enrolled into the trial. 22 households had no undiagnosed child, and one household refused consent. The primary outcome of HIV testing was assessed in 472 (28%) households in the no-incentive group, 654 (39%) households in the $2 incentive group, and 562 (33%) households in the lottery group. At least one child was HIV tested in 93 (20%) households in the no-incentive group, in 316 (48%) households in the $2 incentive group (adjusted odds ratio 3·67, 95% CI 2·77-4·85; p<0·0001), and in 223 (40%) of 562 households in the lottery group (2·66, 2·00-3·55; p<0·0001). No adverse events were reported. INTERPRETATION:Fixed incentives and lottery-based incentives increased the uptake of HIV testing by older children and adolescents, a key hard-to-reach population. This strategy would be sustainable in the context of vertical HIV infection as repeated testing would not be necessary until sexual debut. FUNDING:Wellcome Trust.

journal_name

Lancet HIV

journal_title

The lancet. HIV

authors

Kranzer K,Simms V,Bandason T,Dauya E,McHugh G,Munyati S,Chonzi P,Dakshina S,Mujuru H,Weiss HA,Ferrand RA

doi

10.1016/S2352-3018(17)30176-5

subject

Has Abstract

pub_date

2018-02-01 00:00:00

pages

e79-e86

issue

2

eissn

2405-4704

issn

2352-3018

pii

S2352-3018(17)30176-5

journal_volume

5

pub_type

杂志文章,随机对照试验
  • Association of age, baseline kidney function, and medication exposure with declines in creatinine clearance on pre-exposure prophylaxis: an observational cohort study.

    abstract:BACKGROUND:As pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate and emtricitabine for the prevention of HIV infection is rolled out internationally, strategies to maintain effectiveness and to minimise adverse effects merit consideration. In this study, we aimed to assess reductions in renal function a...

    journal_title:The lancet. HIV

    pub_type: 临床试验,杂志文章

    doi:10.1016/S2352-3018(16)30153-9

    authors: Gandhi M,Glidden DV,Mayer K,Schechter M,Buchbinder S,Grinsztejn B,Hosek S,Casapia M,Guanira J,Bekker LG,Louie A,Horng H,Benet LZ,Liu A,Grant RM

    更新日期:2016-11-01 00:00:00

  • Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, n

    abstract:BACKGROUND:ADVANCE compared the efficacy and safety of two antiretroviral first-line combinations (dolutegravir combined with emtricitabine and either tenofovir disoproxil fumarate or tenofovir alafenamide), with a third regimen (efavirenz combined with emtricitabine and tenofovir disoproxil fumarate) previously recomm...

    journal_title:The lancet. HIV

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/S2352-3018(20)30241-1

    authors: Venter WDF,Sokhela S,Simmons B,Moorhouse M,Fairlie L,Mashabane N,Serenata C,Akpomiemie G,Masenya M,Qavi A,Chandiwana N,McCann K,Norris S,Chersich M,Maartens G,Lalla-Edward S,Vos A,Clayden P,Abrams E,Arulappan N,Hi

    更新日期:2020-10-01 00:00:00

  • Age in antiretroviral therapy programmes in South Africa: a retrospective, multicentre, observational cohort study.

    abstract:BACKGROUND:As access to antiretroviral therapy (ART) expands, increasing numbers of older patients will start treatment and need specialised long-term care. However, the effect of age in ART programmes in resource-constrained settings is poorly understood. The HIV epidemic is ageing rapidly and South Africa has one of ...

    journal_title:The lancet. HIV

    pub_type: 杂志文章,多中心研究

    doi:10.1016/S2352-3018(15)00113-7

    authors: Cornell M,Johnson LF,Schomaker M,Tanser F,Maskew M,Wood R,Prozesky H,Giddy J,Stinson K,Egger M,Boulle A,Myer L,International Epidemiologic Databases to Evaluate AIDS-Southern Africa Collaboration.

    更新日期:2015-09-01 00:00:00

  • Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppr

    abstract:BACKGROUND:Simplified regimens with reduced pill burden and fewer side-effects are desirable for people living with HIV. We investigated the efficacy and safety of switching to a single-tablet regimen of darunavir, cobicistat, emtricitabine, and tenofovir alafenamide versus continuing a regimen of boosted protease inhi...

    journal_title:The lancet. HIV

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1016/S2352-3018(17)30179-0

    authors: Orkin C,Molina JM,Negredo E,Arribas JR,Gathe J,Eron JJ,Van Landuyt E,Lathouwers E,Hufkens V,Petrovic R,Vanveggel S,Opsomer M,EMERALD study group.

    更新日期:2018-01-01 00:00:00

  • Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial.

    abstract:BACKGROUND:Cabotegravir (GSK1265744) is an HIV-1 integrase strand transfer inhibitor with potent antiviral activity and a long half-life when administered by injection that prevented simian-HIV infection upon repeat intrarectal challenge in male macaques. We aimed to assess the safety, tolerability, and pharmacokinetic...

    journal_title:The lancet. HIV

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1016/S2352-3018(17)30068-1

    authors: Markowitz M,Frank I,Grant RM,Mayer KH,Elion R,Goldstein D,Fisher C,Sobieszczyk ME,Gallant JE,Van Tieu H,Weinberg W,Margolis DA,Hudson KJ,Stancil BS,Ford SL,Patel P,Gould E,Rinehart AR,Smith KY,Spreen WR

    更新日期:2017-08-01 00:00:00

  • PrEP awareness and engagement among transgender women in South Africa: a cross-sectional, mixed methods study.

    abstract:BACKGROUND:The South African national HIV plan recommends pre-exposure prophylaxis (PrEP) for transgender women, whose HIV prevalence estimates are as high as 25% in sub-Saharan Africa. The aim of this study was to explore PrEP awareness, uptake, and willingness, as well as associated barriers and facilitators, in orde...

    journal_title:The lancet. HIV

    pub_type: 杂志文章

    doi:10.1016/S2352-3018(20)30119-3

    authors: Poteat T,Malik M,van der Merwe LLA,Cloete A,Adams D,Nonyane BAS,Wirtz AL

    更新日期:2020-12-01 00:00:00

  • Algorithm-guided empirical tuberculosis treatment for people with advanced HIV (TB Fast Track): an open-label, cluster-randomised trial.

    abstract:BACKGROUND:Tuberculosis, which is often undiagnosed, is the major cause of death among HIV-positive people. We aimed to test whether the use of a clinical algorithm enabling the initiation of empirical tuberculosis treatment by nurses in primary health-care clinics would reduce mortality compared with standard of care ...

    journal_title:The lancet. HIV

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/S2352-3018(19)30266-8

    authors: Grant AD,Charalambous S,Tlali M,Karat AS,Dorman SE,Hoffmann CJ,Johnson S,Vassall A,Churchyard GJ,Fielding KL

    更新日期:2020-01-01 00:00:00

  • Effect of expanding opioid agonist therapies on the HIV epidemic and mortality in Ukraine: a modelling study.

    abstract:BACKGROUND:As HIV incidence and mortality continue to increase in eastern Europe and central Asia, particularly among people who inject drugs (PWID), it is crucial to effectively scale-up opioid agonist therapy (OAT), such as methadone or buprenorphine maintenance therapy, to optimise HIV outcomes. With low OAT coverag...

    journal_title:The lancet. HIV

    pub_type: 杂志文章

    doi:10.1016/S2352-3018(19)30373-X

    authors: Tan J,Altice FL,Madden LM,Zelenev A

    更新日期:2020-02-01 00:00:00

  • Prioritising the most needed paediatric antiretroviral formulations: the PADO4 list.

    abstract::Despite considerable progress in paediatric HIV treatment and timely revision of global policies recommending the use of more effective and tolerable antiretroviral regimens, optimal antiretroviral formulations for infants, children, and adolescents remain limited. The Paediatric Antiretroviral Drug Optimization group...

    journal_title:The lancet. HIV

    pub_type: 杂志文章,评审

    doi:10.1016/S2352-3018(19)30193-6

    authors: Penazzato M,Townsend CL,Rakhmanina N,Cheng Y,Archary M,Cressey TR,Kim MH,Musiime V,Turkova A,Ruel TD,Rabie H,Sugandhi N,Rojo P,Doherty M,Abrams EJ,PADO4 participants.

    更新日期:2019-09-01 00:00:00

  • Multi-arm, multi-stage randomised controlled trials for evaluating therapeutic HIV cure interventions.

    abstract::The evaluation of immune-based approaches to achieve an antiretroviral therapy free remission of HIV infection requires proven efficacy through antiretroviral therapy interruption placebo-controlled trials. This approach is not without risk to participants and innovative trial designs need to be developed that minimis...

    journal_title:The lancet. HIV

    pub_type: 杂志文章,评审

    doi:10.1016/S2352-3018(19)30082-7

    authors: Moore CL,Stöhr W,Crook AM,Richert L,Leliévre JD,Pantaleo G,García F,Vella S,Lévy Y,Thiébaut R,McCormack S

    更新日期:2019-05-01 00:00:00

  • Predictors of linkage to HIV care and viral suppression after release from jails and prisons: a retrospective cohort study.

    abstract:BACKGROUND:Incarceration provides an opportunity for engagement in HIV care but is associated with poor HIV treatment outcomes after release. We aimed to assess post-release linkage to HIV care (LTC) and the effect of transitional case management services. METHODS:To create a retrospective cohort of all adults with HI...

    journal_title:The lancet. HIV

    pub_type: 杂志文章

    doi:10.1016/S2352-3018(17)30209-6

    authors: Loeliger KB,Altice FL,Desai MM,Ciarleglio MM,Gallagher C,Meyer JP

    更新日期:2018-02-01 00:00:00

  • From HIV infection to therapeutic response: a population-based longitudinal HIV cascade-of-care study in KwaZulu-Natal, South Africa.

    abstract:BACKGROUND:Standard approaches to estimation of losses in the HIV cascade of care are typically cross-sectional and do not include the population stages before linkage to clinical care. We used indiviual-level longitudinal cascade data, transition by transition, including population stages, both to identify the health-...

    journal_title:The lancet. HIV

    pub_type: 杂志文章

    doi:10.1016/S2352-3018(16)30224-7

    authors: Haber N,Tanser F,Bor J,Naidu K,Mutevedzi T,Herbst K,Porter K,Pillay D,Bärnighausen T

    更新日期:2017-05-01 00:00:00

  • Raltegravir versus efavirenz in antiretroviral-naive pregnant women living with HIV (NICHD P1081): an open-label, randomised, controlled, phase 4 trial.

    abstract:BACKGROUND:Although antiretroviral regimens containing integrase inhibitors rapidly suppress HIV viral load in non-pregnant adults, few published data from randomised controlled trials have compared the safety and efficacy of any integrase inhibitor to efavirenz when initiated during pregnancy. We compared safety and e...

    journal_title:The lancet. HIV

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1016/S2352-3018(20)30038-2

    authors: João EC,Morrison RL,Shapiro DE,Chakhtoura N,Gouvèa MIS,de Lourdes B Teixeira M,Fuller TL,Mmbaga BT,Ngocho JS,Njau BN,Violari A,Mathiba R,Essack Z,Pilotto JHS,Moreira LF,Rolon MJ,Cahn P,Prommas S,Cressey TR,Chokephai

    更新日期:2020-05-01 00:00:00

  • Community-based HIV prevalence in KwaZulu-Natal, South Africa: results of a cross-sectional household survey.

    abstract:BACKGROUND:In high HIV burden settings, maximising the coverage of prevention strategies is crucial to achieving epidemic control. However, little is known about the reach and effect of these strategies in some communities. METHODS:We did a cross-sectional community survey in the adjacent Greater Edendale and Vulindle...

    journal_title:The lancet. HIV

    pub_type: 杂志文章

    doi:10.1016/S2352-3018(18)30104-8

    authors: Kharsany ABM,Cawood C,Khanyile D,Lewis L,Grobler A,Puren A,Govender K,George G,Beckett S,Samsunder N,Madurai S,Toledo C,Chipeta Z,Glenshaw M,Hersey S,Abdool Karim Q

    更新日期:2018-08-01 00:00:00

  • Ending the HIV epidemic in the USA: an economic modelling study in six cities.

    abstract:BACKGROUND:The HIV epidemic in the USA is a collection of diverse local microepidemics. We aimed to identify optimal combination implementation strategies of evidence-based interventions to reach 90% reduction of incidence in 10 years, in six US cities that comprise 24·1% of people living with HIV in the USA. METHODS:...

    journal_title:The lancet. HIV

    pub_type: 杂志文章

    doi:10.1016/S2352-3018(20)30033-3

    authors: Nosyk B,Zang X,Krebs E,Enns B,Min JE,Behrends CN,Del Rio C,Dombrowski JC,Feaster DJ,Golden M,Marshall BDL,Mehta SH,Metsch LR,Pandya A,Schackman BR,Shoptaw S,Strathdee SA,Localized HIV Modeling Study Group.

    更新日期:2020-07-01 00:00:00

  • Conditional cash transfers and uptake of and retention in prevention of mother-to-child HIV transmission care: a randomised controlled trial.

    abstract:BACKGROUND:Novel strategies are needed to increase retention in and uptake of prevention of mother-to-child HIV transmission (PMTCT) services in sub-Saharan Africa. We aimed to determine whether small, increasing cash payments, which were conditional on attendance at scheduled clinic visits and receipt of proposed serv...

    journal_title:The lancet. HIV

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/S2352-3018(15)00247-7

    authors: Yotebieng M,Thirumurthy H,Moracco KE,Kawende B,Chalachala JL,Wenzi LK,Ravelomanana NL,Edmonds A,Thompson D,Okitolonda EW,Behets F

    更新日期:2016-02-01 00:00:00

  • Temporal trends in prognostic markers of HIV-1 virulence and transmissibility: an observational cohort study.

    abstract:BACKGROUND:Measures of CD4 T-cell count and HIV-1 plasma viral load before antiretroviral therapy are proxies for virulence. Whether these proxies are changing over time has implications for prevention and treatment. The aim of this study was to investigate those trends. METHODS:Data were derived from the Concerted Ac...

    journal_title:The lancet. HIV

    pub_type: 杂志文章

    doi:10.1016/S2352-3018(14)00002-2

    authors: Pantazis N,Porter K,Costagliola D,De Luca A,Ghosn J,Guiguet M,Johnson AM,Kelleher AD,Morrison C,Thiebaut R,Wittkop L,Touloumi G,CASCADE Collaboration in EuroCoord.

    更新日期:2014-12-01 00:00:00

  • A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of a Chemokine Receptor 5 (CCR5) Antagonist to Decrease the Occurrence of Immune Reconstitution Inflammatory Syndrome in HIV-Infection: The CADIRIS Study.

    abstract:BACKGROUND:Immune Reconstitution Inflammatory Syndrome (IRIS) is a common complication of antiretroviral therapy (ART) in HIV-infected patients. IRIS is associated with an increased risk of hospitalization and death. We ascertained whether CCR5 blockade using maraviroc reduces the risk of IRIS. METHODS:The CADIRIS stu...

    journal_title:The lancet. HIV

    pub_type: 杂志文章

    doi:10.1016/S2352-3018(14)70027-X

    authors: Sierra-Madero JG,Ellenberg S,Rassool MS,Tierney A,Belaunzarán-Zamudio PF,López-Martínez A,Piñeirúa-Menéndez A,Montaner LJ,Azzoni L,Benítez CR,Sereti I,Andrade-Villanueva J,Mosqueda-Gómez JL,Rodriguez B,Sanne I,Lederman MM,

    更新日期:2014-11-01 00:00:00

  • Effectiveness and cost-effectiveness of potential responses to future high levels of transmitted HIV drug resistance in antiretroviral drug-naive populations beginning treatment: modelling study and economic analysis.

    abstract:BACKGROUND:With continued roll-out of antiretroviral therapy (ART) in resource-limited settings, evidence is emerging of increasing levels of transmitted drug-resistant HIV. We aimed to compare the effectiveness and cost-effectiveness of different potential public health responses to substantial levels of transmitted d...

    journal_title:The lancet. HIV

    pub_type: 杂志文章

    doi:10.1016/S2352-3018(14)70021-9

    authors: Phillips AN,Cambiano V,Miners A,Revill P,Pillay D,Lundgren JD,Bennett D,Raizes E,Nakagawa F,De Luca A,Vitoria M,Barcarolo J,Perriens J,Jordan MR,Bertagnolio S

    更新日期:2014-11-01 00:00:00

  • Unveiling of HIV dynamics among transgender women: a respondent-driven sampling study in Rio de Janeiro, Brazil.

    abstract:BACKGROUND:The burden of HIV in transgender women (transwomen) in Brazil remains unknown. We aimed to estimate HIV prevalence among transwomen in Rio de Janeiro and to identify predictors of newly diagnosed HIV infections. METHODS:We recruited transwomen from Rio de Janeiro, Brazil, by respondent-driven sampling. Elig...

    journal_title:The lancet. HIV

    pub_type: 杂志文章

    doi:10.1016/S2352-3018(17)30015-2

    authors: Grinsztejn B,Jalil EM,Monteiro L,Velasque L,Moreira RI,Garcia AC,Castro CV,Krüger A,Luz PM,Liu AY,McFarland W,Buchbinder S,Veloso VG,Wilson EC,Transcender Study Team.

    更新日期:2017-04-01 00:00:00

  • Tenofovir disoproxil fumarate intravaginal ring for HIV pre-exposure prophylaxis in sexually active women: a phase 1, single-blind, randomised, controlled trial.

    abstract:BACKGROUND:An intravaginal ring that releases the tenofovir prodrug, tenofovir disoproxil fumarate, provided 100% protection in macaques against simian HIV and was safe in a 14-day clinical trial in sexually abstinent women. We aimed to assess the safety and pharmacokinetics of this intravaginal ring over 90 days in se...

    journal_title:The lancet. HIV

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1016/S2352-3018(19)30145-6

    authors: Keller MJ,Wood L,Billingsley JM,Ray LL,Goymer J,Sinclair S,McGinn AP,Marzinke MA,Frank B,Srinivasan S,Liu C,Atrio JM,Espinoza L,Mugo N,Spiegel HML,Anderson PL,Fredricks DN,Hendrix CW,Marrazzo J,Bosinger SE,Herold

    更新日期:2019-08-01 00:00:00

  • Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, ph

    abstract:BACKGROUND:Switching from therapy based on a boosted protease inhibitor to bictegravir, emtricitabine, and tenofovir alafenamide could avoid drug interactions and unwanted side-effects in virologically suppressed adults with HIV-1 infection, while maintaining a high barrier to resistance and providing a simplified once...

    journal_title:The lancet. HIV

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1016/S2352-3018(18)30091-2

    authors: Daar ES,DeJesus E,Ruane P,Crofoot G,Oguchi G,Creticos C,Rockstroh JK,Molina JM,Koenig E,Liu YP,Custodio J,Andreatta K,Graham H,Cheng A,Martin H,Quirk E

    更新日期:2018-07-01 00:00:00

  • Near real-time monitoring of HIV transmission hotspots from routine HIV genotyping: an implementation case study.

    abstract:BACKGROUND:HIV evolves rapidly and therefore infections with similar genetic sequences are likely linked by recent transmission events. Clusters of related infections can represent subpopulations with high rates of transmission. We describe the implementation of an automated near real-time system to monitor and charact...

    journal_title:The lancet. HIV

    pub_type: 杂志文章

    doi:10.1016/S2352-3018(16)00046-1

    authors: Poon AF,Gustafson R,Daly P,Zerr L,Demlow SE,Wong J,Woods CK,Hogg RS,Krajden M,Moore D,Kendall P,Montaner JS,Harrigan PR

    更新日期:2016-05-01 00:00:00

  • Cost-effectiveness of point-of-care testing with task-shifting for HIV care in South Africa: a modelling study.

    abstract:BACKGROUND:The number of people on antiretroviral therapy (ART) requiring treatment monitoring in low-resource settings is rapidly increasing. Point-of-care (POC) testing for ART monitoring might alleviate burden on centralised laboratories and improve clinical outcomes, but its cost-effectiveness is unknown. METHODS:...

    journal_title:The lancet. HIV

    pub_type: 杂志文章

    doi:10.1016/S2352-3018(20)30279-4

    authors: Sharma M,Mudimu E,Simeon K,Bershteyn A,Dorward J,Violette LR,Akullian A,Abdool Karim SS,Celum C,Garrett N,Drain PK

    更新日期:2020-12-18 00:00:00

  • Catalysing the development and introduction of paediatric drug formulations for children living with HIV: a new global collaborative framework for action.

    abstract::Progress in the development and introduction of paediatric formulations for key infectious diseases is poor in low-income and middle-income countries (LMICs). Although major steps have been made in the scale-up of antiretroviral medicines in LMICs, the development and deployment of formulations for infants and childre...

    journal_title:The lancet. HIV

    pub_type: 杂志文章

    doi:10.1016/S2352-3018(18)30005-5

    authors: Penazzato M,Watkins M,Morin S,Lewis L,Pascual F,Vicari M,Lee J,Hargreaves S,Doherty M,Siberry GK

    更新日期:2018-05-01 00:00:00

  • Issues about periconception use of dolutegravir are reminiscent of early concerns about efavirenz.

    abstract::South Africa intends to include dolutegravir in its first-line antiretroviral therapy (ART) regimen because of cost savings, the drug's high barrier to resistance, and efficacy. However, recent data from Botswana suggest potential teratogenicity of dolutegravir. WHO recommends that non-pregnant women of childbearing a...

    journal_title:The lancet. HIV

    pub_type: 杂志文章

    doi:10.1016/S2352-3018(18)30249-2

    authors: Black V,Schwartz SR

    更新日期:2018-12-01 00:00:00

  • Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial.

    abstract:BACKGROUND:All recent treatment guidelines recommend integrase strand transfer inhibitors (INSTIs) as components of initial HIV therapy. Bictegravir, a novel, once-daily, unboosted INSTI, showed potent activity in a 10 day monotherapy study and has a high in-vitro resistance barrier. On the basis of these results, we d...

    journal_title:The lancet. HIV

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/S2352-3018(17)30016-4

    authors: Sax PE,DeJesus E,Crofoot G,Ward D,Benson P,Dretler R,Mills A,Brinson C,Peloquin J,Wei X,White K,Cheng A,Martin H,Quirk E

    更新日期:2017-04-01 00:00:00

  • Universal test and treat and the HIV epidemic in rural South Africa: a phase 4, open-label, community cluster randomised trial.

    abstract:BACKGROUND:Universal antiretroviral therapy (ART), as per the 2015 WHO recommendations, might reduce population HIV incidence. We investigated the effect of universal test and treat on HIV acquisition at population level in a high prevalence rural region of South Africa. METHODS:We did a phase 4, open-label, cluster r...

    journal_title:The lancet. HIV

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/S2352-3018(17)30205-9

    authors: Iwuji CC,Orne-Gliemann J,Larmarange J,Balestre E,Thiebaut R,Tanser F,Okesola N,Makowa T,Dreyer J,Herbst K,McGrath N,Bärnighausen T,Boyer S,De Oliveira T,Rekacewicz C,Bazin B,Newell ML,Pillay D,Dabis F,ANRS 12249 Tas

    更新日期:2018-03-01 00:00:00

  • Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial.

    abstract:BACKGROUND:Doravirine is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) with a pharmacokinetic profile supporting once-daily dosing, and potent in-vitro activity against the most common NNRTI-resistant HIV-1 variants. We compared doravirine with ritonavir-boosted darunavir, when both were given with two...

    journal_title:The lancet. HIV

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1016/S2352-3018(18)30021-3

    authors: Molina JM,Squires K,Sax PE,Cahn P,Lombaard J,DeJesus E,Lai MT,Xu X,Rodgers A,Lupinacci L,Kumar S,Sklar P,Nguyen BY,Hanna GJ,Hwang C,DRIVE-FORWARD Study Group.

    更新日期:2018-05-01 00:00:00

  • Home testing and counselling to reduce HIV incidence in a generalised epidemic setting: a mathematical modelling analysis.

    abstract:BACKGROUND:Home HIV testing and counselling (HTC) achieves high levels of HIV testing and linkage to care. Periodic home HTC, particularly targeted to those with high HIV viral load, might facilitate expansion of antiretroviral therapy (ART) coverage. We used a mathematical model to assess the effect of periodic home H...

    journal_title:The lancet. HIV

    pub_type: 杂志文章

    doi:10.1016/S2352-3018(16)30009-1

    authors: Ying R,Sharma M,Celum C,Baeten JM,van Rooyen H,Hughes JP,Garnett G,Barnabas RV

    更新日期:2016-06-01 00:00:00